This year, World Blood Donor Day will once again be celebrated around the world on 14 June! The event serves to thank voluntary, unpaid blood donors for their life-saving gifts of blood and also to raise awareness of the need for regular blood donations to ensure that all individuals and ...

  This fall TIF is coming to Germany✈️✈️ and is more than excited to announce its forthcoming Capacity Building Workshop for Patients’ Associations and people with thalassaemia and other haemoglobinopathies, which will take place on 11-13 October, 2019 in Hamburg, Germany!!! Sponsorship opportunities are available to #patients with thalassaemia from countries ...

  TIF with support from Celgene Corporation, has developed a disease specific e-registry with health record for patients with thalassaemia. This e-registry is now completed, as a first version, and is ready to be piloted in selected centres in Cyprus, Greece and Bulgaria. After piloting and user comments, the e-registry ...

An educational leaflet with important information for β-thalassaemia patients on hematopoietic stem cell transplantation (HSCT), more commonly known as bone marrow transplantation (BMT). English

  A significant number of gene therapy approaches are currently undergoing clinical trials, some of which are already producing encouraging results. The Bluebird Bio’s gene therapy product, under the name ZYNTEGLO™, has received positive comments from the scientific committees of the European drug regulatory authority (EMA). This means that the practical ...

  TIF’s Board of Directors Member and Expert Patient, Mr. George Constantinou, and TIF’s collaborators Dr. phil Eva-Maria Knoll and Dr. Anne Yardumian, were delegated to visit Austria on 11-13 April, 2019, a country of special focus for the THALIA project, due to the fact that it has become a ...

In its most severe form and without adequate care, thalassaemia can be lethal in early childhood, and although  International Thalassaemia Day has come and gone, awareness is paramount.   Andrew Obenshain, Head of Europe at gene therapy company bluebird bio, looks into what it means to live with thalassaemia, with ...

  A comprehensive article by Carsten W. Lederer (PhD), Petros Patsali (PhD), Panayiota Papasavva (MD, MSc), Thessalia Papasavva (PhD) and Marina Kleanthous (PhD, Head of the MGTD), on the thalassaemia carrier status of Cypriots, and the therapy developments in the country.        

What did 1,500 patient groups from different countries and therapy areas think of pharmaceutical companies in 2018? To what extent did these companies meet patients‘ expectations?   A recent survey conducted by Patient View unveils the patients‚ perspective on the reputation and performance of 46 companies in the healthcare industry, ...